Researchers at the Kennedy Institute and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, working with clinicians at NHS Lothian, have found that injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules results in the reduction of the cell characteristics responsible for progression of Dupuytren’s disease.
Based on their laboratory data that tumour necrosis factor (TNF) drives the development of myofibroblasts, the cell type that causes Dupuytren’s disease, the research team explored the effect of an anti-TNF drug injected directly into the Dupuytren’s nodule tissue. The results so far are very promising.
“Our data have shown that a concentrated formulation of adalimumab injected directly into the diseased tissue may be effective in targeting the cells responsible for Dupuytren’s disease,” said Jagdeep Nanchahal, MD, PhD, University of Oxford Professor of Hand, Plastic and Reconstructive Surgery, who led the study.
“This brings new hope to people who suffer from this disabling condition, who currently have to wait for their situation to be deteriorate, watching their hand lose function until it is bad enough for surgery. And then there’s the lengthy recovery ahead, a less than ideal situation to find yourself in.”
This randomised trial (phase 2a) recruited 28 patients with Dupuytren’s disease who were scheduled to have surgery in Edinburgh to remove diseased tissue in their hand. Two weeks prior to surgery they received a single injection of varying doses of the anti-TNF drug, or placebo. The tissue removed during surgery, which is usually discarded, was then analysed in the laboratory. The team found that adalimumab (at a dose of 40mg formulated in 0.4ml) reduces expression of the fibrotic markers, -smooth muscle actin (-SMA) and type I procollagen, at 2 weeks post injection, suggesting this drug could be used to stop the growth of disease causing myofibroblast cells. They also found the drug to be safe and well tolerated.
The findings are published on line in the journal EBioMedicine, published by The Lancet.
Dupuytren’s disease is a common condition of the hand that affects 4% of the UK population and causes the fingers to curl irreversibly into the palm. There is currently no NICE approved treatment for early disease and typically people are told to return to their GP once their fingers become so bent that their hand function is impaired.
The anti-TNF drug adalimumab (Humira) is currently licensed in the EU for the treatment of a number of conditions including rheumatoid arthritis, Crohn’s disease and ulcerative colitis and overall has an excellent safety profile.
“We are delighted to have received further funding from the Wellcome Trust and Department of Health to test whether adalimumab will work for patients with early stage Dupuytren’s disease,” said Professor Sir Marc Feldmann, co-author and former director of the Kennedy Institute. In conjunction with Professor Sir Ravinder Maini, Sir Marc identified TNF as a therapeutic target in patients with rheumatoid arthritis.
“The Kennedy Institute has a long history of successfully translating laboratory findings to the clinic'” said Professor Fiona Powrie, Director of the Institute. “This type of work requires close collaboration between laboratory scientists, clinical trialists and clinician scientists over many years”.
The researchers are continuing to investigate the use of this drug to treat Dupuytren’s disease in a phase 2b trial called the RIDD trial, which is currently running in Oxford and Edinburgh.
The Latest on: Dupuytren’s disease
via Google News
The Latest on: Dupuytren’s disease
- Advances in Minimally Invasive Treatment of Hand Disorderson February 18, 2021 at 4:00 pm
New studies regarding less invasive treatment of Dupuytren’s disease and cubital tunnel syndrome (ulnar nerve entrapment at the elbow) have been reported in the past two years and have begun to ...
- Ask the Expert: What Are the Signs Dupuytren’s Contracture Is Progressing?on February 18, 2021 at 11:12 am
An expert weighs in on the progression rate of Dupuytren's contracture, along with potential treatment options for the disease.
- Neurodevelopment and Cognition in Children after Enterovirus 71 Infectionon February 17, 2021 at 4:00 pm
Enterovirus 71 is a common cause of hand, foot, and mouth disease and encephalitis in Asia and elsewhere. The long-term neurologic and psychiatric effects of this viral infection on the central ...
- Grillo Center: Finger deformity develops slowlyon February 16, 2021 at 3:03 pm
Q: In his later years, my father developed a finger deformity that his doctor called a Dupuytren’s contracture. Can you tell me about this condition? A: Dupuytren’s contracture is a condition ...
- Clostridium Difficile Diagnostics and Treatment Marketon February 8, 2021 at 8:37 pm
X million by 2027, starting at XXX. X million in 2019. Clostridium difficile is a disease caused by bacteria. Symptoms of the disease includes diarrhea, nausea, colon inflammation, and others.
- Dupuytren's Contracture Market Overview, Dynamics, Growth Factors for Business Expansion, Key Companies, Trends and Forecast 2023on February 4, 2021 at 2:33 am
The exact causes of Dupuytren's contracture are unknown however the risk factors include alcoholism, smoking, thyroid problems, liver disease, diabetes, previous hand trauma, epilepsy, family ...
- A Penis Problem: Peyronie's Diseaseon February 3, 2021 at 12:00 am
Peyronie’s is also linked to other conditions, such as Dupuytren’s (contracture of the hand) or Ledderhose (contracture of the bottoms of the feet) diseases. There is currently no way to prevent ...
- Genome-wide meta-analysis of muscle weakness identifies 15 susceptibility loci in older men and womenon January 28, 2021 at 3:16 am
Disease diagnoses were either self-reported, hospital diagnosed, or inferred from relevant surgical procedures (for example Palmar Fasciectomy to treat Dupuytren’s contracture), and hip or knee ...
- Heart disease remains the leading cause of death worldwideon January 27, 2021 at 12:27 pm
Heart disease remains the leading cause of death worldwide, according to the 2021 Statistical Update from the American Heart Association, written by a collaboration of healthcare professionals led by ...
via Bing News